Investigational drug · Phase 2
MT218
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for MRI Scan.
Phase 2Last checked: Nov 19, 2026Latest source record: Dec 19, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "MT218"
First trial start
2024
Jul 25, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MT218", any sponsor or status.
Conditions studied
As listed on its trial records.
- MRI Scan
Largest trials
Live from ClinicalTrials.gov: studies naming "MT218" as an intervention, largest first.
- Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer PatientsRecruiting
Songqi GaoIndustry
NCT06262139 · 12 participants (planned) · Start Jul 25, 2024 · Primary completion Dec 2026
Drug: MT218 injection · For: MRI Scan
Sites: Atlanta, Georgia
Newest research
PubMed records naming it or its code names, newest first.
- MR molecular imaging for monitoring and predicting tumor responses to immunotherapy.
Laney VEA, Zhao W, Hwang IM, et al. · Theranostics 2025
- MR Molecular Image Guided Treatment of Pancreatic Cancer with Targeted ECO/miR-200c Nanoparticles in Immunocompetent Mouse Tumor Models.
Laney V, Hall R, Yuan X, et al. · Pharm Res 2024
- MR Molecular Imaging of Extradomain-B Fibronectin for Assessing Progression and Therapy Resistance of Prostate Cancer.
Vaidya A, Shankardass A, Buford M, et al. · Chem Biomed Imaging 2024
- Assessment of the Efficacy of the Combination of RNAi of lncRNA DANCR with Chemotherapy to Treat Triple Negative Breast Cancer Using Magnetic Resonance Molecular Imaging.
Nicolescu C, Kim J, Sun D, et al. · Bioconjug Chem 2024
- Pharmacokinetics and Tolerability of the Cancer-Targeting MRI Contrast Agent MT218 in Healthy Males.
Li Y, Apseloff G, Tweedle MF, et al. · Invest Radiol 2024
- A New Era in Magnetic Resonance Contrast Media.
Runge VM, Heverhagen JT · Invest Radiol 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.